Hemogenyx is a biotechnology company quoted on the LSE Standard List. The Company is developing novel therapies for blood diseases which aim to offer a safer and more accessible patient pathway than current practice. Although the products are at the preclinical stage, the Company is already generating revenue through multiple collaborations with biopharmaceutical companies.
24 Jan 2019
Initiation of research: Disrupting current blood disease therapy
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Initiation of research: Disrupting current blood disease therapy
HemoGenyx Pharmaceuticals Plc (HEMO:LON) | 1.6 0 (-1.8%) | Mkt Cap: 22.0m
- Published:
24 Jan 2019 -
Author:
Liam Gascoigne-Cohen -
Pages:
26
Hemogenyx is a biotechnology company quoted on the LSE Standard List. The Company is developing novel therapies for blood diseases which aim to offer a safer and more accessible patient pathway than current practice. Although the products are at the preclinical stage, the Company is already generating revenue through multiple collaborations with biopharmaceutical companies.